managing residual disease after neoadjuvant therapy in breast cancer
Published 7 years ago • 481 plays • Length 2:53Download video MP4
Download video MP3
Similar videos
-
7:11
case 1: adjuvant therapy for residual disease in her2 breast cancer
-
2:25
reducing risk in residual breast cancer
-
1:16
tackling residual disease in breast cancer
-
20:11
residual cancer burden after neoadjuvant therapy and long-term survival outcomes in breast cancer
-
10:28
residual cancer burden after neoadjuvant therapy and long-term survival outcomes in breast cancer
-
1:29
the predictive value of treatment response after neoadjuvant therapy
-
3:12
neoadjuvant versus adjuvant therapy in tnbc
-
38:56
robotic surgeries in cancer treatment | kauvery podcast | episode-1| kauvery hospital chennai
-
47:29
optimizing therapy in her2 disease with dr. reshma mahtani
-
38:22
adjuvant/neoadjuvant therapy for breast cancer: updates and molecular predictors of benefit
-
7:22
residual cancer burden after neoadjuvant therapy and long-term survival outcomes in breast cancer
-
3:10
practical approach to the management of the axilla after neoadjuvant chemotherapy
-
0:55
neoadjuvant treatment approach for her2 positive breast cancer
-
8:22
the immune landscape of residual tnbc after neoadjuvant chemotherapy
-
49:25
optimizing therapy in her2 disease with dr. hope s. rugo
-
19:35
treatment options in patients with residualr (tnbc) following neoadjuvant ctx dr. meteb al-foheidi
-
10:28
axillary management of node-positive breast cancer after neoadjuvant chemotherapy
-
0:48
dr. william sikov on triple-negative breast cancer patients not responding to treatment
-
6:54
no pcr in patients after neoadjuvant chemotherapy in tnbc